You searched for: who were post liver transplant (Engelska - Maltesiska)

liver transplant
trapjant tal-fwied

post-liver transplant n = 53
wara trapjant tal-fwied n=53

liver transplant patients
pazjenti li jirċievu trapjant tal-fwied

lung and liver transplant populations
popolazzjonijiet li kellhom trapjant tal-pulmun u tal-fwied

if you have had a liver transplant
jekk kellek trapjant tal-fwied;

liver transplant recipients - study 0126
pazjenti li jirċievu trapjant tal-fwied - studju 0126

liver transplant patients without cirrhosis
pazjenti bi fwied ittrapjantat mingħajr ċirrosi

advanced cirrhosis and post-liver transplant (ally-1)
Ċirrożi avvanzata u wara trapjant tal-fwied (ally-1)

clinical trial in liver transplant recipients
provi kliniċi f’reċipjenti ta’ trapjant tal-fwied

recurrent hcv infection post-liver transplant (gt 1, 3 or 4)
infezzjoni b’hcv rikorrenti għal wara trapjant tal-fwied (gt 1, 3 jew 4)

side effects before or after having a liver transplant
effetti sekondarji qabel jew wara trapjant tal-fwied

0.11 to 0.13 mg per kg daily in those who have had a liver transplant.
0.11 sa 0.13 mg għal kull kg kuljum f’dawk li kellhom trapjant tal-fwied.

you have recently had, or soon expect to have, a liver transplant
jekk dan l-aħħar kellek, jew jekk qed tistenna dalwaqt, trapjant tal-fwied

modigraf was effective at preventing organ rejection in children who had had a liver transplant.
modigraf kien effikaċi fil-prevenzjoni tar-rifjut tal-organu fit-tfal sottoposti għal trapjant tal-fwied.

interim data from a phase 2 study in 11 hcv infected post-liver transplant patients.
tagħrif interim minn studju ta’ fażi 2 fi 11-il pazjent infettat b’hcv wara trapjant tal-fwied.

in liver transplant, the starting dose is 0.10 to 0.20 mg/ kg.
fil- każ ta 'trapjant tal- fwied, id- doża tal- bidu hi 0. 10 sa 0. 20 mg/ kg.

in the de novo liver transplant study, 29 subjects were treated with envarsus.
fl-istudju tat-trapjant tal-fwied de novo, 29 pazjent kienu kkurati b’envarsus.

10% of liver transplant recipients had a modification of their immunosuppressive agents.
10% ta’ dawk li rċivew trapjant tal-fwied kellhom modifika tal-mediċini immunosoppressivi tagħhom.

sovaldi in combination with ribavirin is recommended for 24 weeks in liver transplant recipients.
sovaldi użat flimkien ma’ ribavirin hu rakkomandat għal 24 ġimgħa f’pazjenti li jirċievu trapjant tal- fwied.

in the liver transplant study, the patient received mmf and corticosteroids as concomitant treatment.
fl-istudju tat- trapjant tal-fwied, il-pazjent irċieva mmf u kortikosterjodi bħala kura fl-istess ħin.